References
- TonelliMSacksFPfefferMGaoZCurhanGRelation between serum phosphate level and cardiovascular event rate in people with coronary diseaseCirculation20051121726272633 Erratum in: Circulation2007;116(23):e55616246962
- ZhengCMLuKCWuCCHsuYHLinYFAssociation of serum phosphate and related factors in ESRD-related vascular calcificationInt J Nephrol2011 Epub May 25, 2011
- NakaiSAkibaTKazamaJEffects of serum calcium, phosphorus, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in JapanTher Apher Dial2008121495418257812
- BlockGAKlassenPSLazarusJMOfsthunNLowrieEGChertowGMMineral metabolism, mortality, and morbidity in maintenance hemodialysisJ Am Soc Nephrol20041582208221815284307
- KuriharaSMarumoFAluminum and iron deposition in dialysis patientsNihon Rinsho199250Suppl905910 Japanese1578787
- ChertowGMBurkeSKRaggiPfor Treat to Goal Working GroupSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney Int200262124525212081584
- OkaYMiyazakiMTakatsuSSevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosageTher Apher Dial200711210711317381531
- PaiABSheplerBMComparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implicationsPharmacotherapy200929555456119397463
- AlbaajFHutchisonAJLanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patientsExpert Opin Pharmacother20056231932815757427
- DammentSJShenVAssessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic ratsClin Nephrol200563212713715730055
- JoyMSFinnWFfor LAM-302 Study GroupRandomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemiaAm J Kidney Dis20034219610712830461
- ShigematsuTfor Lanthanum Carbonate Research GroupLanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysisTher Apher Dial2008121556118257813
- KawanishiHIshidaMIshizakiMLanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPDPerit Dial Int200828667367518981401
- ShigematsuTKonoTSatohKPhosphate overload accelerates vascular calcium deposition in end-stage renal disease patientsNephrol Dial Transplant200318Suppl 3iii86iii8912771310
- ShigematsuTfor Lanthanum Carbonate Research GroupMulticenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemiaClin Nephrol200870540441019000540
- SpragueSMRossEANathSDZhangPPrattRDKrauseRLanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover studyClin Nephrol200972425225819825330
- HutchisonAJBarnettMEKrauseRKwanJTSiamiGAfor SPD405-309 Lanthanum Study GroupLong-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatmentNephron Clin Pract20081101c15c23 Erratum in: Nephron Clin Pract2008;110(1):c2318667837
- HutchisonAJBarnettMEKrauseRJSiamiGAfor Lanthanum Carbonate Study GroupLanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysisClin Nephrol200971328629519281739
- FinnWFJoyMSfor LAM-308 Study GroupA long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysisCurr Med Res Opin200521565766415969865
- SpragueSMA comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonateCurr Med Res Opin200723123167317517991307
- ShigematsuTfor Lanthanum Carbonate Research GroupThree-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patientsClin Exp Nephrol201014658959720814807
- D’HaesePCSpasovskiGBSikoleAA multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patientsKidney Int Suppl200385S73S7812753271
- MallucheHHSiamiGASwanepoelCImprovements in renal osteodystrophy in patients treated with lanthanum carbonate for two yearsClin Nephrol200870428429518826853
- ShigematsuTTokumotoANakaokaAArisakaHEffect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemiaTher Apher Dial201115217618421426511
- BehetsGJDamsGVercauterenSRDoes the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?J Am Soc Nephrol20041582219222815284308
- AltmannPBarnettMEFinnWFfor SPD405-307 Lanthanum Carbonate Study GroupCognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapyKidney Int200771325225917035945
- SlatopolskyELiapisHFinchJProgressive accumulation of lanthanum in the liver of normal and uremic ratsKidney Int20056862809281316316357
- Ben-DovIZPappoOSklair-LevyMLanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic ratsNephrol Dial Transplant200722236236817090605
- BervoetsAJBehetsGJSchryversDHepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failureKidney Int200975438939819052535
- GotoSKomabaHMoriwakiKClinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in JapanClin J Am Soc Nephrol2011661375138421551021
- GutiérrezOMMannstadtMIsakovaTFibroblast growth factor 23 and mortality among patients undergoing hemodialysisN Engl J Med2008359658459218687639
- ShigematsuTNegiSfor the COLC Research GroupCombined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study)Nephrol Dial Transplant20122731050105421771755
- Gonzalez-ParraEGonzalez-CasausMLGalánALanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patientsNephrol Dial Transplant20112682567257121436379
- HayashiHMachidaMSekineTYamaguchiHKiriyamaTKumitaSBeam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysisJpn J Radiol201028432232420512553
- FürstenbergABuscombeJDavenportAOverestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney diseaseAm J Nephrol201032542543120861616
- ChanMRYevzlinASHinshawMJafferyJBCalciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapyWMJ2008107733533819180873
- MuneSShibataMHatamuraIMechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosisClin Exp Nephrol200913657157719655218
- ToussaintNDLauKKPolkinghorneKRKerrPGAttenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trialNephrology (Carlton)201116329029821342323